low dose aspirin breast cancer

Low-Dose Aspirin Slows Breast Cancer Cell Growth

Low-dose aspirin could slow the growth of breast cancer cells. That’s the amazing result of a new study presented on Sunday at the American Society for Biochemistry and Molecular Biology annual meeting in Boston. The presenter was Gargi Maity, lead author of the new research.

A team working at the Veterans Affairs Medical Center in Kansas City, Missouri and the University of Kansas Medical Center has discovered that small but regular doses of aspirin slow down the growth of breast cancer tumors in lab mice. In addition, the aspirin seemed to prevent the cancer from spreading as easily.

Although they used mouse models, it’s possible that the inexpensive wonder drug could also work in humans. They discovered that the aspirin blocked cancer cells from being able to completely form stem cells, which in turn blocked their ability to grow.

Senior author Sushanta Banerjee said that conventional chemotherapy doesn’t impact stem cells, which sometimes allows cancers to return. The team was particularly interested in looking at the effect of aspirin on triple negative breast cancer, a rare form of breast cancer that doesn’t respond well to tamoxifen, a highly regarded drug that helps survival rates with some other forms of breast cancer.

Over 12 percent of American women will develop breast cancer at some point in their lives. The risk increases with age, but some women have a mutation that puts them at much higher risk of developing the disease.

Low-dose aspirin has been an inexpensive method for reducing the risk of heart attack and stroke for years. Because it reduces your blood’s clotting ability, then you shouldn’t just take up the treatment on your own, even though aspirin is sold over-the-counter.

The Benefit of Aspirin to Cut Cancer Risk

Your doctor must tell you if you’re a good candidate to take children’s or another form of low-dose aspirin to prevent future disease.

[aspirin photo by Tomasz Wyszolmirski via Shutterstock]

Comments